Curasight A/S appoints CRO to run Phase 2 study with uTRACE[®] in prostate cancer
· Phase 2 study is part of the collaboration between Curasight and Curium announced earlier this year · Appointment of clinical CRO marks further step in progress in development of uTRACE as a potential new diagnostic solution for prostate cancer Copenhagen, December 13, 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) today announced it has signed an agreement with ABX-CRO, an experienced international clinical research organization serving the pharmaceutical industry, to run the phase 2 study investigating uTRACE[®] in improving the diagnosis of prostate cancer.